Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Estradiol gel for bone loss and fat mass changes during androgen deprivation therapy in men with prostate cancer
ACTRN12614000689673Phase 3Terminated
- Sponsor
- University of Melbourne
- Start
- Nov 2017
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Hypogonadism and osteoporosis comparing Estradiol gel with Placebo gel (2 arms). Primary endpoints: Total volumetric bone mineral density at tibia and Total fat mass. Started Nov 2017; status: terminated.
02
Drugs
estradiol
03
Conditions
Hypogonadismosteoporosis
Beyond the preview
Go deeper on ACTRN12614000689673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12614000689673.